Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Stoke Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Stoke Therapeutics's regulatory disclosures and financial reporting.
Stoke Therapeutics, Inc. (STOK) reported that its Chief Medical Officer, Barry Ticho, sold a total of 5,545 shares of common stock on September 1, 2026 in open-market transactions under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales were executed in multiple trades at weighted average prices within disclosed ranges.
Stoke Therapeutics, Inc. (STOK) reported insider equity activity by its Chief Medical Officer, Barry Ticho. On August 14, 2026, he exercised 10,000 performance stock units, receiving 10,000 shares of common stock at a price of $0.00 per share. On August 18, 2026, the company facilitated issuer-mandated sales of 4,525 and 242 common shares, respectively, to satisfy tax withholding liabilities tied to restricted stock unit vesting, at weighted average prices around $32 per share across specified price ranges.
Stoke Therapeutics, Inc. (STOK) reported insider activity by director Edward M. Kaye, MD. On August 14, 2026, he exercised 26,250 performance stock units, receiving an equal number of common shares and reducing that PSU award to 0. On August 18, 2026, a total of 12,567 common shares were sold in open-market transactions at weighted average prices of $32.01 and $32.47 per share, in each case as an issuer-mandated sale to satisfy tax withholding liabilities related to equity vesting.
Stoke Therapeutics, Inc. (STOK) reported insider equity activity by officer Jonathan Allan (General Counsel & Corporate Secretary). On August 14, 2026, Allan exercised 6,000 Performance Stock Units into 6,000 shares of common stock at a stated price of $0.00 per share, reducing that PSU award balance to zero. The award’s achievement had been certified on August 14, 2025, with half vesting then and the remainder vesting on August 14, 2026, subject to continued service. On August 18, 2026, the broker sold a total of 2,861 common shares in open-market transactions at weighted average prices of $32.01$32.47 per share, in an issuer-mandated sale to satisfy tax withholding liabilities related to restricted stock unit vesting and settlement.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of Stoke Therapeutics, Inc. common stock. They report an aggregate 4,038,404 shares of common stock, representing 6.5% of the class, based on 62,240,347 shares outstanding as of March 31, 2026.
The Reporting Persons have no sole voting or dispositive power over these shares and instead report shared voting and shared dispositive power over all 4,038,404 shares. The shares are held by Lynx1 Master Fund LP and a managed account, and the Lynx1 Fund has the right to receive dividends and sale proceeds from the reported shares. The statement notes that the filing should not be construed as an admission that any Reporting Person is the beneficial owner for all purposes.
The Toronto-Dominion Bank and TD Securities Inc. report beneficial ownership of Stoke Therapeutics, Inc. common stock. Together they report holding 3,183,258 shares of common stock, representing 4.9% of the class. TD Bank has sole voting and dispositive power over 3,173,258 shares, while TD Securities Inc. has sole voting and dispositive power over 10,000 shares. Neither entity reports any shared voting or dispositive power. TD Bank is the sole owner of TD Securities Inc. and may be deemed to hold an indirect interest in the shares held by TD Securities Inc., but disclaims beneficial ownership of those shares except to the extent of its pecuniary interest. The reporting persons state that they are not part of any group with respect to Stoke Therapeutics securities and jointly file this statement under Rule 13d-1(k).
FMR LLC filed an amended Schedule 13G reporting passive ownership of STOKE THERAPEUTICS INC common stock. FMR LLC and related entities beneficially own 5,313,100 shares of common stock, representing 8.5% of the class. FMR LLC reports sole voting power over 5,312,516 shares and sole dispositive power over 5,313,100 shares, with no shared voting or dispositive power. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over 5,313,100 shares and no voting power. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no single such person holds more than five percent of the outstanding common stock.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported selling 7,176 shares of common stock on August 3, 2026 in two open-market or private transactions, at weighted-average prices of $28.9501 and $29.4539 per share, under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales occurred in price ranges of $28.36–$29.35 and $29.36–$29.54 per share, respectively.
Stoke Therapeutics, Inc. filed a prospectus supplement relating to the offer and sale of up to $200,000,000 of common stock as “Placement Shares” under its existing Controlled Equity Sales Agreement with Cantor Fitzgerald & Co., structured as an at-the-market offering.
The prospectus supplement forms part of Stoke’s automatic shelf registration statement on Form S-3ASR (File No. 333-294402), originally filed March 18, 2026. A legal opinion from Fenwick & West LLP covering the Placement Shares is included as Exhibit 5.1, with a related consent and Inline XBRL cover data also provided.
Stoke Therapeutics, Inc. is updating its at-the-market equity program under a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. to offer and sell up to $200,000,000 of common stock from time to time on The Nasdaq Global Select Market. Cantor will act as sales agent on a commercially reasonable efforts basis and receive up to 3.0% of gross proceeds as commissions, and will be deemed an underwriter.
As context, 62,402,595 shares of common stock were outstanding as of June 30, 2026, and approximately 4.7 million shares had previously been sold under the Sales Agreement for $146.4 million in net proceeds pursuant to an earlier supplement, which this document supersedes. Assuming the full $200,000,000 is sold at $28.86 per share, net tangible book value would increase from $5.54 to $7.81 per share, implying $21.05 per-share dilution to new investors.
Stoke currently intends to use any net proceeds primarily for general corporate purposes, including research, clinical and process development, manufacturing, commercialization preparations, working capital, potential debt reduction, and possible acquisitions or in-licensing of complementary products, technologies, or businesses.